Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP 3A4/5 activity.

Pharmacopsychiatry - 1 Jul 2006

Stephan P L, Jaquenoud Sirot E, Mueller B, Eap C B, Baumann P

Abstract excerpt

A 47-year-old male taxi driver experienced multiple adverse drug reactions during therapy with clomipramine (CMI) and quetiapine for major depressive disorder, after having been unsuccessfully treated with adequate doses of mirtazapine and venlafaxine. Drug serum concentrations of CMI and quetiapine were significantly increased and pharmacogenetic testing showed a poor metabolizer status for CYP2D6, low CYP3A4/5...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents
Share to Antidepressive Agents, Tricyclic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antipsychotic Agents

Share to Cholelithiasis

Share to Cytochrome P-450 CYP2D6

Share to Cytochrome P-450 CYP3A

Share to Cytochrome P-450 Enzyme System

Share to Depressive Disorder, Major

Source

Identifiers

PMID: 16871470
DOI: 10.1055/s-2006-946705

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP 3A4/5 activity.PMID 16871470Read ↗

Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient.Semantic proximity Read ↗

Influence of combined CYP2C19 and CYP2D6 phenotypes on adverse drug reactions in patients with major depressive disorder: a clinical cohort studySemantic proximity Read ↗

Novel CYP2D6 and CYP2C19 variants identified in a patient with adverse reactions towards venlafaxine monotherapy and dual therapy with nortriptyline and fluoxetineSemantic proximity Read ↗

Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping.Semantic proximity Read ↗

Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.Semantic proximity Read ↗

Influence of combined CYP2C19 and CYP2D6 phenotypes on adverse drug reactions in patients with major depressive disorder: a clinical cohort study.Semantic proximity Read ↗

A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication.Semantic proximity Read ↗

Serotonin toxicity in a CYP2D6 poor metabolizer, initially diagnosed as a drug-resistant major depression.Semantic proximity Read ↗

Prolonged toxicity after amitriptyline overdose in a patient deficient in CYP2D6 activity.Semantic proximity Read ↗

No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.Semantic proximity Read ↗

Tolerance to desvenlafaxine in rapid metabolizing depressed patients.Semantic proximity Read ↗

Safety and side effect profile of fluoxetine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.